VALENCIA, Calif. and MELBOURNE, Australia, September 28, 2022 (GLOBE NEWSWIRE) — AVITA Medical, Inc. RCELA VH)), a regenerative medicine company leader in the development and commercialization of first-in-class devices and autologous cell therapies for skin repair, today announced the appointment of James Corbett as Chief Executive Officer, effective immediately. Mr. Corbett, who served as a non-executive director, will continue to serve as an executive director of AVITA Medical, Inc.’s board of directors.

Mr. Corbett has nearly 40 years of life sciences experience and has been CEO of several public companies including: Microtherapeutics Inc., ev3 Inc and Alphatec Spine. Mr. Corbett has extensive global, commercial and operational experience, having served as expatriate general manager of Baxter Japan, followed by leading global commercialization as general manager and president of Scimed Life Systems and Boston Scientific International, respectively. Mr. Corbett later led the development and initial public offering of ev3 Inc. and was CEO of three privately held companies; Home Diagnostics Inc., Vertos Medical Inc. and CathWorks LTD.

“Jim is a seasoned strategist with significant commercial expertise that positions him well to lead AVITA Medical through the next phase of growth and beyond,” said Lou Panaccio, CEO of AVITA Medical. “Having completed a thorough process using a leading executive search firm, I am confident that Jim is the right executive for the company at this time.”

“The opportunities offered by the RECELLĀ® System and the anticipated expansion of indications make this a particularly exciting time to be part of AVITA Medical’s leadership team,” said Mr. Corbett. “We are well positioned to execute a commercial growth strategy with upcoming new indications that will allow us to continue to improve lives and outcomes for our patients.”

Mr. Corbett becomes Dr. Follow Michael…


Source story